Free Trial

Allspring Global Investments Holdings LLC Has $24.45 Million Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Regeneron Pharmaceuticals logo with Medical background

Allspring Global Investments Holdings LLC reduced its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 8.8% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 39,630 shares of the biopharmaceutical company's stock after selling 3,844 shares during the quarter. Allspring Global Investments Holdings LLC's holdings in Regeneron Pharmaceuticals were worth $24,452,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. Pinney & Scofield Inc. bought a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter worth $25,000. Rakuten Securities Inc. lifted its position in shares of Regeneron Pharmaceuticals by 62.5% during the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock worth $28,000 after buying an additional 15 shares during the last quarter. OFI Invest Asset Management bought a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter worth $28,000. E Fund Management Hong Kong Co. Ltd. lifted its position in shares of Regeneron Pharmaceuticals by 344.4% during the 1st quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company's stock worth $25,000 after buying an additional 31 shares during the last quarter. Finally, Avalon Trust Co bought a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter worth $36,000. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Trading Down 0.5%

NASDAQ REGN traded down $2.74 during trading hours on Friday, hitting $545.00. 456,413 shares of the company's stock were exchanged, compared to its average volume of 907,387. The stock has a 50-day simple moving average of $549.38 and a 200 day simple moving average of $625.94. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.49 and a 1-year high of $1,211.20. The firm has a market cap of $58.84 billion, a price-to-earnings ratio of 13.87, a PEG ratio of 2.00 and a beta of 0.33. The company has a current ratio of 4.93, a quick ratio of 4.03 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing the consensus estimate of $8.83 by ($0.61). Regeneron Pharmaceuticals had a return on equity of 15.27% and a net margin of 31.94%. The business had revenue of $3.03 billion for the quarter, compared to analyst estimates of $3.40 billion. During the same period in the prior year, the business earned $9.55 EPS. The company's revenue for the quarter was down 3.7% on a year-over-year basis. On average, equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, June 6th. Shareholders of record on Tuesday, May 20th were paid a $0.88 dividend. The ex-dividend date was Tuesday, May 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.65%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is presently 8.96%.

Analysts Set New Price Targets

Several equities analysts have commented on REGN shares. The Goldman Sachs Group dropped their target price on Regeneron Pharmaceuticals from $917.00 to $804.00 and set a "buy" rating for the company in a research report on Wednesday, April 30th. Guggenheim reiterated a "buy" rating on shares of Regeneron Pharmaceuticals in a research report on Friday, May 30th. Bank of America dropped their target price on Regeneron Pharmaceuticals from $575.00 to $547.00 and set an "underperform" rating for the company in a research report on Thursday, April 17th. BMO Capital Markets dropped their target price on Regeneron Pharmaceuticals from $800.00 to $600.00 and set an "outperform" rating for the company in a research report on Monday, June 2nd. Finally, Canaccord Genuity Group upgraded Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, April 22nd. One analyst has rated the stock with a sell rating, seven have issued a hold rating, sixteen have assigned a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $822.58.

View Our Latest Analysis on Regeneron Pharmaceuticals

Regeneron Pharmaceuticals Profile

(Free Report)

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Further Reading

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Should You Invest $1,000 in Regeneron Pharmaceuticals Right Now?

Before you consider Regeneron Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Regeneron Pharmaceuticals wasn't on the list.

While Regeneron Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

ALERT: Big Tech Earnings – Watch Before Wednesday
ACT FAST! Congress is Dumping these 3 Stocks
3 “Boring” Mega Cap Stocks to Turn Into Pure Profit

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines